WO2004087095A3 - Dispositif osmotique contenant du zafirlukast et un antagoniste h1 - Google Patents

Dispositif osmotique contenant du zafirlukast et un antagoniste h1 Download PDF

Info

Publication number
WO2004087095A3
WO2004087095A3 PCT/CR2004/000004 CR2004000004W WO2004087095A3 WO 2004087095 A3 WO2004087095 A3 WO 2004087095A3 CR 2004000004 W CR2004000004 W CR 2004000004W WO 2004087095 A3 WO2004087095 A3 WO 2004087095A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
zafirlukast
controlled release
release device
device containing
Prior art date
Application number
PCT/CR2004/000004
Other languages
English (en)
Spanish (es)
Other versions
WO2004087095A2 (fr
Inventor
Juan A Vergez
Joaquina Faour
Marcelo F Befumo
Original Assignee
Osmotica Costa Rica Sa
Juan A Vergez
Joaquina Faour
Marcelo F Befumo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Costa Rica Sa, Juan A Vergez, Joaquina Faour, Marcelo F Befumo filed Critical Osmotica Costa Rica Sa
Publication of WO2004087095A2 publication Critical patent/WO2004087095A2/fr
Publication of WO2004087095A3 publication Critical patent/WO2004087095A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un dispositif de libération contrôlée, par exemple, un dispositif osmotique libérant du zafirlukast de manière contrôlée et un antagoniste H1 de manière rapide et/ou immédiate. Un large éventail d'antagonistes H1 antihistaminiques, notamment la loratadine, peuvent être utilisés dans ce dispositif. Des modes de réalisation spécifiques de cette invention concernent des dispositifs osmotiques libérant du zafirlukast et un antagoniste H1 de manière contrôlée et pendant une période étendue de temps depuis le noyau. Les dispositifs servent au traitement de l'asthme, d'inflammations et de réactions allergiques.
PCT/CR2004/000004 2003-03-31 2004-03-30 Dispositif osmotique contenant du zafirlukast et un antagoniste h1 WO2004087095A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45909803P 2003-03-31 2003-03-31
US60/459,098 2003-03-31

Publications (2)

Publication Number Publication Date
WO2004087095A2 WO2004087095A2 (fr) 2004-10-14
WO2004087095A3 true WO2004087095A3 (fr) 2005-07-21

Family

ID=33131864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CR2004/000004 WO2004087095A2 (fr) 2003-03-31 2004-03-30 Dispositif osmotique contenant du zafirlukast et un antagoniste h1

Country Status (1)

Country Link
WO (1) WO2004087095A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073702A2 (fr) 2005-12-29 2007-07-05 Osmotica Corp. Comprime a couches multiples a liberation par triple combinaison
CN104958279A (zh) * 2015-06-27 2015-10-07 万特制药(海南)有限公司 氯雷他定口腔速溶膜及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
WO1997028797A1 (fr) * 1996-02-08 1997-08-14 Merck & Co., Inc. Procede de traitement et composition pharmaceutique
WO1999032125A1 (fr) * 1997-12-23 1999-07-01 Schering Corporation Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
US20020102305A1 (en) * 2000-01-13 2002-08-01 Joaquina Faour Osmotic device containing pseudoephedrine and an H1antagonist
CA2337571A1 (fr) * 2001-02-20 2002-08-20 Asta Medica Aktiengesellschaft Combinaisons d'antihistaminique et d'antagoniste de leucotriene
WO2002080916A1 (fr) * 2001-04-03 2002-10-17 Kaura Sita R Traitement d'affection respiratoire et composition a cet effet
US20030044457A1 (en) * 2001-07-17 2003-03-06 Joaquina Faour Drug delivery device containing oseltamivir and an H1 antagonist
US20030055077A1 (en) * 2000-04-12 2003-03-20 Jones Thomas R. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
WO2003068186A1 (fr) * 2002-02-11 2003-08-21 Lipocine, Inc. Formulations pharmaceutiques et systemes d'absorption et de liberation a multiples phases d'agents actifs

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
WO1997028797A1 (fr) * 1996-02-08 1997-08-14 Merck & Co., Inc. Procede de traitement et composition pharmaceutique
WO1999032125A1 (fr) * 1997-12-23 1999-07-01 Schering Corporation Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
US20020102305A1 (en) * 2000-01-13 2002-08-01 Joaquina Faour Osmotic device containing pseudoephedrine and an H1antagonist
US20030055077A1 (en) * 2000-04-12 2003-03-20 Jones Thomas R. Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
CA2337571A1 (fr) * 2001-02-20 2002-08-20 Asta Medica Aktiengesellschaft Combinaisons d'antihistaminique et d'antagoniste de leucotriene
WO2002080916A1 (fr) * 2001-04-03 2002-10-17 Kaura Sita R Traitement d'affection respiratoire et composition a cet effet
US20030044457A1 (en) * 2001-07-17 2003-03-06 Joaquina Faour Drug delivery device containing oseltamivir and an H1 antagonist
WO2003068186A1 (fr) * 2002-02-11 2003-08-21 Lipocine, Inc. Formulations pharmaceutiques et systemes d'absorption et de liberation a multiples phases d'agents actifs

Also Published As

Publication number Publication date
WO2004087095A2 (fr) 2004-10-14

Similar Documents

Publication Publication Date Title
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
EP1710696B8 (fr) Dispositif a semi-conducteurs et procede d'activation de celui-ci
EP1942905A4 (fr) Agonistes des recepteurs de l'acide nicotinique, compositions contenant ces composes et methodes de traitement
IL179595A0 (en) Substituted indazoles, compositions containing same, preparation and use
EP1874301A4 (fr) Agonistes du recepteur de la niacine, compositions les contenant et methodes de traitement
AP2004003161A0 (en) Substituted benzazoles and use thereof as raf kinase inhibitors.
WO2006116348A3 (fr) Compositions destinees a des dispositifs medicaux contenant des combinaisons d'agents dans des volumes controles
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
IL188329A0 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP1608361A4 (fr) Compositions d'inhibiteurs selectifs de cyclooxygenase-2 et d'agonistes 5-ht1b/1 d destinees au traitement et a la prevention de migraines
EP1904143A4 (fr) Dispositif de protection embolique et procedes d'utilisation
EP1776148A4 (fr) Dispositifs ophtalmiques et procedes et compositions associes
EP1941558A4 (fr) Dispositif piézoélectrique et son procédé d'actionnement, appareil piézoélectrique, et appareil de décharge de liquide
EP1756949A4 (fr) Dispositif a semi-conducteur et son procede de formation
TWI368320B (en) Solid state imaging device, manufacturing method of the same, and substrate for solid state imaging device
WO2005112903A3 (fr) Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central
EP1971602A4 (fr) Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
EP1751175A4 (fr) Antagonistes du recepteur de l'interleukine-1, compositions, et methodes de traitement
EP1717246B8 (fr) Antagonistes du tnf, et inhibiteurs du tnf les contenant en tant qu'ingredient actif
TWI366779B (en) Pointing device and the method of emulating pointing device
AP2006003794A0 (en) Combinations of substituted 1-phenyl-1,5-dihydropyrido-Ä3,2-bÜindol-2-ones and other HIV inhibitors
EP1940402A4 (fr) Agonistes du recepteur de l'acide nicotinique, compositions contenant ces composes et methodes de traitement
AU2003209528A1 (en) Method and device for activating bluetooth devices through signaling
WO2006116311A3 (fr) Composes agonistes des recepteurs opioides et leur utilisation dans le traitement de la douleur
SI1791872T1 (sl) Biotinilirani heksadekasaharidi, farmacevtski sestavki in njihova uporaba

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase